Michael Henderson, Chief Executive Officer of Apogee Therapeutics, Inc. (NASDAQ: APGE), executed a transaction disposing of 20,000 shares of common stock on July 8, 2026. The total value of the sale was $2,672,600. The shares were sold at a weighted average price of $133.63 per share, with individual transaction prices ranging from $133.52 to $133.70. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. The sale comes as Apogee shares trade at $133.65, near their 52-week high of $133.87, following a remarkable 250% gain over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, placing it among the most overvalued stocks in the market. The company's market capitalization stands at $10.01 billion.
Additionally, on July 10, 2026, Mr. Henderson gifted 75,046 shares of Apogee Therapeutics common stock. This transaction involved a bona fide gift of securities to a donor advised fund. Following these transactions, Mr. Henderson directly holds 920,941 shares of Apogee Therapeutics common stock.
In other recent news, Apogee Therapeutics announced it has entered into a definitive agreement to be acquired by AbbVie for $135.11 per share in cash, valuing the company at approximately $10.9 billion. This acquisition follows the development of Apogee's lead program, zumilokibart, which is entering Phase III trials. In response to the acquisition, Mizuho downgraded Apogee's stock to Neutral from Buy, citing the acquisition agreement, and adjusted its price target to $135 from $110. Similarly, UBS downgraded the stock to Neutral, raising its price target to $135.11 from $100, viewing the acquisition price as full and fair given the current development stage of Apogee's assets. Apogee Therapeutics Follow Analyze APGE Included in our AI-picked strategies Review strategies 133.65 ▲ +0.08 (+0.06%) Closed · 15:59:59 · USD 133.41 ▼ -0.24 (-0.18%) After Hours · 19:20:53 1D 1W 1M 6M 1Y 5Y Max Created with Highcharts 11.4.8 14:00 15:00 16:00 17:00 18:00 19:00 133.2 133.4 133.6 Analyze APGE Additionally, Apogee has signed two agreements with Paragon Therapeutics for the discovery and development of antibodies targeting the interleukin 31 receptor (IL-31R). These agreements include compensation to Paragon for research activities and potential additional fees for manufacturing tasks. At Apogee's 2026 Annual Meeting of Stockholders, shareholders elected directors and approved proposals, with 61,853,254 shares eligible to vote. Meanwhile, RBC Capital raised its price target on Apogee's stock to $97, maintaining a Sector Perform rating, based on dermatologists' survey results regarding the potential future use of zumilokibart in atopic dermatitis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Is your APGE trade worth the risk? Before you click "buy," know exactly where to set your stop-loss. Our Vision AI literally "sees" your APGE chart and delivers a complete risk management plan—entry, stop-loss, and profit target—in under 60 seconds. Protect your downside. Validate every trade. Invest smarter. July Sale - 60% Off InvestingPro
Apogee Therapeutics CEO Michael Henderson sold 20,000 shares worth $2.67 million on July 8, 2026, under a pre-existing trading plan. The transaction coincides with the company's pending acquisition by AbbVie for $135.11 per share in cash, valuing Apogee at approximately $10.9 billion. Following the acquisition announcement, several analysts have adjusted their price targets and ratings for Apogee's stock, which currently trades near its 52-week high of $133.87.
Summarize with
Key Points
- Apogee Therapeutics CEO Michael Henderson sold 20,000 shares worth $2.67 million under a Rule 10b5-1 plan adopted in August 2025.
- Apogee entered a definitive agreement to be acquired by AbbVie for $135.11 per share in cash, valuing the company at approximately $10.9 billion.
- Analysts Mizuho and UBS downgraded Apogee's stock to Neutral following the acquisition announcement, while RBC Capital raised its price target to $97.
Risks
- The acquisition agreement may introduce integration risks for the biopharmaceutical sector as AbbVie absorbs Apogee's assets, including the Phase III candidate zumilokibart.
- Regulatory and approval uncertainties remain for Apogee's lead program, zumilokibart, as it enters Phase III trials for atopic dermatitis treatment.
- Market valuation concerns are highlighted by analysis suggesting Apogee's stock is overvalued relative to its Fair Value estimate, potentially impacting investor sentiment in the biotech sector.